KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Return on Sales (2017 - 2026)

Aquestive Therapeutics has reported Return on Sales over the past 9 years, most recently at 0.02% for Q4 2025.

  • For Q4 2025, Return on Sales fell 1.0% year-over-year to 0.02%; the TTM value through Dec 2025 reached 0.02%, down 1.0%, while the annual FY2025 figure was 0.02%, 1.0% down from the prior year.
  • Return on Sales for Q4 2025 was 0.02% at Aquestive Therapeutics, down from 0.01% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.01% in Q1 2023 and troughed at 0.06% in Q2 2021.
  • A 5-year average of 0.01% and a median of 0.01% in 2021 define the central range for Return on Sales.
  • Biggest five-year swings in Return on Sales: fell -2bps in 2021 and later increased 4bps in 2022.
  • Year by year, Return on Sales stood at 0.03% in 2021, then soared by 56bps to 0.01% in 2022, then soared by 47bps to 0.01% in 2023, then crashed by -134bps to 0.01% in 2024, then plummeted by -70bps to 0.02% in 2025.
  • Business Quant data shows Return on Sales for AQST at 0.02% in Q4 2025, 0.01% in Q3 2025, and 0.01% in Q2 2025.